Security key
71880W501
Phio Pharmaceuticals Corp. - Common Stock, $0.0001 par value per share (PHIO)
CUSIP: 71880W501
Q1 2026 13F Holders as of 31 Mar 2026
- Type / Class
- Equity / Common Stock, $0.0001 par value per share
- Shares outstanding
- 12,067,869
- Total 13F shares
- 668,490
- Share change
- +274,248
- Total reported value
- $814,950
- Price per share
- $1.22
- Number of holders
- 24
- Value change
- +$346,788
- Number of buys
- 17
- Number of sells
- 6
Report period
Q1 2026
Institutions
24
Top holders
10
PHIO full security history
Previous quarter: Q4 2025
Phio Pharmaceuticals Corp. SEC filings
Phio Pharmaceuticals Corp. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 71880W501
Recent filing periods:
Top shareholders of PHIO - Phio Pharmaceuticals Corp. - Common Stock, $0.0001 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| CVI Investments, Inc. |
13D/G
|
— |
9.9%
|
1,194,719
|
$1,409,768 | +$544,422 | 31 Dec 2025 | |
| INTRACOASTAL CAPITAL, LLC |
13D/G
|
Mitchell P. Kopin |
9.1%
|
1,142,556
|
$1,348,216 | +$840,816 | 31 Dec 2025 | |
| Orca Capital AG |
13D/G
|
— |
4.9%
|
538,707
|
$770,351 | -$231,251 | 08 Dec 2025 | |
| Robert J. Bitterman |
3/4/5
|
Chairman, Pres. & CEO, Director |
3.4%
|
411,421
|
$419,649 | +$31,265 | 05 Feb 2026 | |
| Lisa Cabott Carson |
3/4/5
|
Chief Financial Officer |
0.78%
|
94,000
|
$95,880 | — | 05 Feb 2026 | |
| Patricia A. Bradford |
3/4/5
|
Director |
0.38%
|
45,651
|
$46,564 | — | 05 Feb 2026 | |
| Robert L. Ferrara |
3/4/5
|
Director |
0.32%
|
38,766
|
$82,959 | +$6,050 | 11 Sep 2025 | |
| David H. Deming |
3/4/5
|
Director |
0.31%
|
37,800
|
$38,556 | — | 05 Feb 2026 | |
| Curtis Lockshin |
3/4/5
|
Director |
0.29%
|
35,155
|
$35,858 | — | 05 Feb 2026 | |
| Jonathan E. Freeman |
3/4/5
|
Director |
0.27%
|
32,655
|
$33,308 | — | 05 Feb 2026 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.77%
|
92,638
|
$97,269 | — | 31 Dec 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
0.73%
|
87,628
|
$92,009 | — | 31 Dec 2025 | |
| Cetera Investment Advisers |
13F
|
Company |
0.35%
|
42,500
|
$44,625 | — | 31 Dec 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.2%
|
23,758
|
$24,946 | — | 31 Dec 2025 | |
| DRW Securities, LLC |
13F
|
Company |
0.19%
|
22,636
|
$23,767 | — | 31 Dec 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.17%
|
20,091
|
$21,096 | — | 31 Dec 2025 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.12%
|
14,494
|
$15,219 | — | 31 Dec 2025 | |
| StoneX Group Inc. |
13F
|
Company |
0.1%
|
11,828
|
$12,419 | — | 31 Dec 2025 | |
| Robertson Stephens Wealth Management, LLC |
13F
|
Company |
0.09%
|
10,800
|
$11,340 | — | 31 Dec 2025 | |
| Virtu Financial LLC |
13F
|
Company |
0.08%
|
10,214
|
$11,000 | — | 31 Dec 2025 | |
| CAPTRUST FINANCIAL ADVISORS |
13F
|
Company |
0.08%
|
10,000
|
$10,500 | — | 31 Dec 2025 | |
| UBS Group AG |
13F
|
Company |
0.07%
|
8,594
|
$9,024 | — | 31 Dec 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.05%
|
6,000
|
$6,300 | — | 31 Dec 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.01%
|
1,413
|
$1,483 | — | 31 Dec 2025 | |
| SBI Securities Co., Ltd. |
13F
|
Company |
0.01%
|
1,135
|
$1,192 | — | 31 Dec 2025 | |
| ASSETMARK, INC |
13F
|
Company |
0%
|
110
|
$116 | — | 31 Dec 2025 | |
| Activest Wealth Management |
13F
|
Company |
0%
|
9
|
$9 | — | 31 Dec 2025 | |
| Gerrit Dispersyn |
3/4/5
|
President & CEO, Director |
—
class O/S missing
|
212,327
|
$320,614 | — | 01 Mar 2022 | |
| H. Paul Dorman |
3/4/5
|
Director |
—
class O/S missing
|
20,370
|
$30,759 | — | 15 Feb 2022 | |
| Caitlin Kontulis |
3/4/5
|
Secretary & VP Finance & Admin |
—
class O/S missing
|
10,643
|
$10,196 | — | 01 Mar 2024 | |
| Robert M. Infarinato |
3/4/5
|
VP, CFO |
—
class O/S missing
|
11,000
|
$8,140 | — | 11 Sep 2024 | |
| Geert Cauwenbergh |
3/4/5
|
Director |
—
class O/S missing
|
4,235
|
$6,395 | — | 17 Feb 2023 |
Institutional Holders of Phio Pharmaceuticals Corp. - Common Stock, $0.0001 par value per share (PHIO) as of Q1 2026
As of 31 Mar 2026,
Phio Pharmaceuticals Corp. - Common Stock, $0.0001 par value per share (PHIO) was held by
24 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
668,490 shares.
The largest 10 holders included
GEODE CAPITAL MANAGEMENT, LLC, JANE STREET GROUP, LLC, VANGUARD CAPITAL MANAGEMENT LLC, Cetera Investment Advisers, VANGUARD FIDUCIARY TRUST CO, HRT FINANCIAL LP, TWO SIGMA INVESTMENTS, LP, Scientech Research LLC, UBS Group AG, and XTX Topco Ltd.
This page lists
24
institutional shareholders reporting positions in this security
for the Q1 2026 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q1 2026 vs Q4 2025 Across Filers
Q4 2025 holders
17
Q1 2026 holders
24
Holder diff
7
| Investor | Q4 2025 Shares | Q1 2026 Shares | Share Diff | Share Chg % | Q4 2025 Value $ | Q1 2026 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.